Prospective Grant of an Exclusive Patent License: Concatenated L2 Peptide Based Human Papillomavirus Vaccines, 56621-56622 [2017-25744]
Download as PDF
<![CDATA[
56621
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
REPORTING REQUIREMENTS—Continued
Regulatory/section
requirements
Number of
respondents
Responses
per
respondent
Total annual
responses
Hours per
response
Total burden
hours
57.311(a), Disability Cancellation .................................
57.315(a)(1)(ii), Administrative Hearings ......................
57.316(a), Administrative Hearings ..............................
16
0
0
1
0
0
16
0
0
1
0
0
16
0
0
NSL Subtotal .........................................................
........................
........................
........................
........................
7,567
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Amy McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2017–25750 Filed 11–28–17; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Concatenated L2
Peptide Based Human Papillomavirus
Vaccines
National Institutes of Health.
Notice.
AGENCY:
ACTION:
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive patent license to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to BravoVax Co.,
Ltd located in Wuhan, China.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before December 14, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Kevin W. Chang, Ph.D., Senior
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
pmangrum on DSK3GDR082PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702 Telephone: (240)–276–6910;
Facsimile: (240)–276–5504 Email:
changke@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent
Application No. 60/649,249 filed
February 1, 2005 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS
Reference No. E–103–2005/0–US–01];
United States Provisional Patent
Application No. 60/697,655 filed July 7,
2005 and entitled, ‘‘Papillomavirus L2
N-terminal Peptides For The Induction
Of Broadly Cross-neutralizing
Antibodies’’ [HHS Reference No.
E–103–2005/1–US–01]; United States
Provisional Patent Application No. 60/
752,268 filed December 21, 2005 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Reference No. E–103–2005/2–US–01];
International PCT Application No. PCT/
US2006/003601 filed February 1, 2006,
and entitled, ‘‘Papillomavirus L2
N-terminal Peptides For The Induction
Of Broadly Cross-neutralizing
Antibodies’’ [HHS Reference No. E–
103–2005/3–PCT–01]; United States
Patent No. 8,404,244, issued March 26,
2013 and entitled, ‘‘Papillomavirus L2
N-terminal Peptides For The Induction
Of Broadly Cross-neutralizing
Antibodies’’ [HHS Ref. No. E–103–2005/
3–US–02]; United States Patent No.
9,388,221 issued July 12, 2016 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Ref. No. E–103–2005/3–US–10];
Canadian Patent No. 2,596,698 issued
May 16, 2017 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–CA–03]; Australian
Patent No. 2006210792 issued
November 8, 2012 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Cross-
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
neutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–AU–04]; Japanese Patent
No. 5224821 issued March 22, 2013 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Ref. No. E–103–2005/3–JP–05];
Brazilian Patent Application No.
PI0607097–3 filed February 1, 2006 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Ref. No. E–103–2005/3–BR–06]; Chinese
Patent No. 200680011079.1 issued
March 27, 2013 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–CN–07]; Indian Patent
No. 263255 issued October 16, 2014 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Ref. No. E–103–2005/3–IN–08];
European Patent No. 1853307 issued
December 14, 2016 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–EP–09]; German Patent
No. 1853307 issued December 14, 2016
and entitled, ‘‘Papillomavirus L2 Nterminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies’’
[HHS Ref. No. E–103–2005/3–DE–11];
French Patent No. 1853307 issued
December 14, 2016 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–FR–12]; and United
Kingdom Patent No. 1853307 issued
December 14, 2016 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–GB–13]. The patent
rights in these inventions have been
assigned and/or exclusively licensed to
the government of the United States of
America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘Development and use of
E:\FR\FM\29NON1.SGM
29NON1
56622
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
pmangrum on DSK3GDR082PROD with NOTICES1
concatenated L2 peptides for the
prevention of Human Papillomavirus
(HPV) infection and associated diseases.
Specifically excluded from the field of
use are L2 based virus-like particles
(VLPs), L1/L2 chimeric peptides, and
L1/L2 chimeric peptide/protein based
VLPs.’’
The subject technologies are
papillomavirus L2 capsid protein based
vaccines against HPV. The L2 protein is
the minor papillomavirus capsid protein
for papillomaviruses. It is known that
antibodies to this protein can neutralize
homologous infection. Furthermore, L2
proteins can induce cross-neutralizing
antibodies. Specifically, epitopes at the
N-terminus of L2 shared by cutaneous
and mucosal types of papillomavirus
types and by types that infect divergent
species are broadly cross-neutralizing.
These epitopes at the N-terminus of L2
can be used to elicit cross-neutralizing
antibodies against different types of
HPV.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 14, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–25744 Filed 11–28–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
V Review.
Date: February 5–6, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Washingtonian
Marriott, 9751 Washingtonian Boulevard,
Gaithersburg, MD 20878.
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W618,
Bethesda, MD 20892–9750, 240–276–6611,
mukesh.kumar3@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Molecular
and Cellular Analysis Technologies.
Date: February 8, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Nadeem Khan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W260, Bethesda, MD 20892–
9750, 240–276–5856, nadeem.khan@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
VI Review.
Date: February 8–9, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Washingtonian
Marriott, 9751 Washingtonian Boulevard,
Gaithersburg, MD 20878.
Contact Person: Anita T. Tandle, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W248,
Bethesda, MD 20892–9750, 240–276–5007,
tandlea@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Quantitative Imaging.
Date: February 14, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
4W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Eduardo E. Chufan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W254, Bethesda, MD 20892–
9750, 240–276–7975, chufanee@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 22, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25732 Filed 11–28–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: T-Cells Transduced with HLA
A11 Restricted CT–RCC HERV–E
Reactive T-Cell Receptors for the
Treatment of Renal Cell Carcinoma
National Institutes of Health.
Notice.
AGENCY:
ACTION:
The National Heart, Lung, and
Blood Institute (‘‘NHLBI’’), an institute
of the National Institutes of Health; an
agency within the Department of Health
and Human Services, is contemplating
the grant of an Exclusive Patent License
to commercialize the invention(s)
embodied in the intellectual property
estate stated in the Summary
Information section of this notice to
T-Cure Bioscience, Inc. located in
Thousand Oaks, California and
incorporated under the laws of
Delaware.
DATES: Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
SUMMARY:
E:\FR\FM\29NON1.SGM
29NON1
]]>Agencies
[Federal Register Volume 82, Number 228 (Wednesday, November 29, 2017)]
[Notices]
[Pages 56621-56622]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25744]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Concatenated L2
Peptide Based Human Papillomavirus Vaccines
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an exclusive patent license to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this notice to BravoVax Co.,
Ltd located in Wuhan, China.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before December 14, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Kevin W. Chang, Ph.D., Senior Technology Transfer Manager,
NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-
9702 Telephone: (240)-276-6910; Facsimile: (240)-276-5504 Email:
changke@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 60/649,249 filed
February 1, 2005 and entitled, ``Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Cross-neutralizing Antibodies'' [HHS
Reference No. E-103-2005/0-US-01]; United States Provisional Patent
Application No. 60/697,655 filed July 7, 2005 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Reference No. E-103-2005/1-US-01];
United States Provisional Patent Application No. 60/752,268 filed
December 21, 2005 and entitled, ``Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Cross-neutralizing Antibodies'' [HHS
Reference No. E-103-2005/2-US-01]; International PCT Application No.
PCT/US2006/003601 filed February 1, 2006, and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Reference No. E-103-2005/3-PCT-
01]; United States Patent No. 8,404,244, issued March 26, 2013 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-US-
02]; United States Patent No. 9,388,221 issued July 12, 2016 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-US-
10]; Canadian Patent No. 2,596,698 issued May 16, 2017 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-CA-03];
Australian Patent No. 2006210792 issued November 8, 2012 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-AU-04];
Japanese Patent No. 5224821 issued March 22, 2013 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-JP-05];
Brazilian Patent Application No. PI0607097-3 filed February 1, 2006 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-BR-
06]; Chinese Patent No. 200680011079.1 issued March 27, 2013 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-CN-
07]; Indian Patent No. 263255 issued October 16, 2014 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-IN-08];
European Patent No. 1853307 issued December 14, 2016 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-EP-09];
German Patent No. 1853307 issued December 14, 2016 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-DE-11];
French Patent No. 1853307 issued December 14, 2016 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-FR-12]; and
United Kingdom Patent No. 1853307 issued December 14, 2016 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-GB-
13]. The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of Licensed Patent Rights
for the following: ``Development and use of
[[Page 56622]]
concatenated L2 peptides for the prevention of Human Papillomavirus
(HPV) infection and associated diseases. Specifically excluded from the
field of use are L2 based virus-like particles (VLPs), L1/L2 chimeric
peptides, and L1/L2 chimeric peptide/protein based VLPs.''
The subject technologies are papillomavirus L2 capsid protein based
vaccines against HPV. The L2 protein is the minor papillomavirus capsid
protein for papillomaviruses. It is known that antibodies to this
protein can neutralize homologous infection. Furthermore, L2 proteins
can induce cross-neutralizing antibodies. Specifically, epitopes at the
N-terminus of L2 shared by cutaneous and mucosal types of
papillomavirus types and by types that infect divergent species are
broadly cross-neutralizing. These epitopes at the N-terminus of L2 can
be used to elicit cross-neutralizing antibodies against different types
of HPV.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: November 14, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2017-25744 Filed 11-28-17; 8:45 am]
BILLING CODE 4140-01-P
